Stock BLTE BELITE BIO, INC
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Belite Bio, Inc

Equities

BLTE

US07782B1044

Real-time Estimate Cboe BZX
Other stock markets
 02:58:40 2024-05-21 pm EDT 		5-day change 1st Jan Change
44.74 USD -0.94% Intraday chart for Belite Bio, Inc +7.62% -1.20%
May. 14 Transcript : Belite Bio, Inc, Q1 2024 Earnings Call, May 14, 2024
May. 14 Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
GL
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
AQ
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GL
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
GL
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
AQ
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
GL
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
GL
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
GL
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
GL
Belite Bio Announces $25 Million Registered Direct Offering
GL
Belite Bio : Initiates Stargardt Disease Clinical Trial in Japan
PU
Belite Bio : Announces MHRA Submission of Tinlarebant for Stargardt Disease Clinical Trial in the United Kingdom
PU
Belite Bio : Submits US IND Amendment to Initiate a Phase 2/3 Clinical Trial of Tinlarebant in Stargardt Disease
PU
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
GL
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
GL
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GL
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
GL
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
AQ
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
GL
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BLTE Stock
  4. News Belite Bio, Inc
  5. Press Releases
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW